The Catalyst

Most Recent Posts

10.29.13 | By Mit Spears

Yesterday, I had the opportunity to speak at a conference of regulatory and compliance professionals – those who are dedicated to ensuring that regulation works.

10.29.13 | By Matt Bennett

Millions of prescriptions are filled every year in the United States and the patients who depend on these medications must have confidence in their safety and authenticity.

10.29.13 | By John Castellani

A survey commissioned earlier this year by PhRMA shows 86 percent of Americans believe developing cures for more forms of cancer should be one of the top national health priorities.

10.28.13 | By Jeff Trewhitt

Until this morning, on the rare occasions when I thought of Omaha, Nebraska, I would conjure up images of Warren Buffett, thick juicy steaks, a clean quiet Midwestern city and friendly, laid-back folks, not necessarily in that order.

I learned today that I was not inaccurate, all of the above is true,  but my picture was far from complete.

10.25.13 | By Dr. Bill Chin

Alzheimer’s has proven to be a stubborn, puzzling and perhaps even symbolic disease. In recent years, it has emerged as one of our greatest tests of biopharmaceutical science because of the disease’s vast and growing impact on the health of our aging population and the viability of our health care system.

10.24.13

Today, PhRMA will be hosting a stakeholder action group meeting with the National Council for Prescription Drug Programs (NCPDP) called “Maximizing Prescription Quality Through ePrescribing.” NCPDP is a non-for-profit, American National Standards Institute (ANSI) certified standards development organization.

10.24.13 | By John Castellani

How can we continue to advance cancer research and improve patient outcomes in an era of cost containment?  The issue was recently highlighted in a New York Magazine article that only provided part of the story on cancer progress and cost containment.  Last week I had the opportunity to tackle this question as part of a roundtable that convened leaders from across the cancer community.

10.22.13 | By Matt Bennett

According to the American Cancer Society, nearly one of every two people will develop a cancer at some point in their life.

10.22.13 | By John Castellani

Today, I’ll be speaking to state-wide leaders in California regarding the state’s fight against obesity.

10.22.13 | By Jeff Francer

This year, biopharmaceutical companies committed to transforming how their clinical research can be used to advance innovation for patients through careful sharing of clinical trial data with independent researchers. 

10.21.13 | By John Castellani

More than 30 million Americans suffer from rare diseases – conditions that are classified as such because they affect fewer than 200,000 people in the United States.

10.20.13 | By Karl Uhlendorf

Earlier this month, Bill Chin announced on this blog that PhRMA will be hosting a forum along with the Alzheimer’s Association and the Alzheimer’s Drug Discovery Foundation on Wednesday, October 23rd.

10.18.13 | By Kaelan Hollon

Tuesday began Medicare Part D Open Enrollment. With the program still going strong 10 years after it was enacted, Part D represents a significant milestone for patients.

10.18.13 | By Stephanie Fischer

The cultural anthropologist Margaret Mead once said, “Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has.”

10.17.13 | By Jay Taylor

As the 12 countries negotiating the Trans-Pacific Partnership (TPP) approach the finish line after years of hard work on an ambitious agreement, there remains quite a bit of work left to be done. Now that all the low hanging fruit has been picked, the most difficult issues remain to be finalized. Not surprisingly, intellectual property (IP) is one of those issues 

Pages